Germ‐line Mutation Analysis in Patients with von Hippel‐Lindau Disease in Japan: An Extended Study of 77 Families

We have previously reported on the analysis of germ‐line mutations in Japanese von Hippel‐Lindau disease (VHL) patients and found mutations in 26 families. We have now extended these studies to include an additional 41 VHL families. Germ‐line mutation of the VHL, gene was screened by DNA‐SSCP, direct sequencing, and Southern blot analysis. To summarize all of the data we have studied in this and our previous report, germ‐line mutations have been detected in 55 of 77 (73%) (type 1: 41 / 62 (66%) and type 2: 14/15 (93%)) families. We found similarities in the nature of germ‐line mutations including mutational incidence, location, and DNA substitution patterns between Japanese and Western VHL. These similarities may reflect the predominance of endogenous mutational processes. We also found several interesting characteristics in Japanese VHL. Twenty of 41 (49%) intragenic mutations were unique and not reported in the Western VHL. Four mutations (Arg113Stop, Gln132Stop, Leu158Val, and Cys162Tyr) previously characterized as type 1 mutations were identified in the type 2 (with pheochromocytoma) Japanese families. Genotype‐phenotype correlation study suggested non‐missense mutations predicted to result in the loss of VHL function were associated with the occurrence of renal cell carcinoma, as in sporadic tumors. Our data add to the diversity of VHL germ‐line mutations and provide a better understanding of VHL disease in terms of both clinical management and molecular pathogenesis.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  D. Mukhopadhyay,et al.  An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. , 1999, Biochemical and biophysical research communications.

[3]  T. Shuin,et al.  Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. , 1999, Biochemical and biophysical research communications.

[4]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[5]  S. Richard,et al.  Third International Meeting on von Hippel-Lindau disease. , 1999, Cancer research.

[6]  S. Elledge,et al.  Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. , 1999, Science.

[7]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[8]  W. Kaelin,et al.  pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Burk,et al.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Louis,et al.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.

[11]  W. Kaelin,et al.  Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.

[12]  A. Vortmeyer,et al.  Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. , 1997, The American journal of pathology.

[13]  D. Mukhopadhyay,et al.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity , 1997, Molecular and cellular biology.

[14]  S. Richard,et al.  Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. , 1997, American journal of human genetics.

[15]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[16]  O. Hino,et al.  Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. , 1996, Cancer research.

[17]  T. Shuin,et al.  Molecular Genetic Diagnosis of von Hippel‐Lindau Disease: Analysis of Five Japanese Families , 1996, Japanese journal of cancer research : Gann.

[18]  L. Schmidt,et al.  Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. , 1995, Human pathology.

[19]  S. Chew,et al.  Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. , 1995, Journal of medical genetics.

[20]  Fan,et al.  Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. , 1995, Cancer research.

[21]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[22]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[23]  Knudson Ag.  VHL gene mutation and clear-cell renal carcinomas. , 1995 .

[24]  R. Klausner,et al.  Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Seizinger,et al.  Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. , 1995, Cancer research.

[26]  M. Ferguson-Smith,et al.  Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.

[27]  T. Shuin,et al.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. , 1994, Cancer research.

[28]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[29]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[30]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[31]  S. Sommer.  Assessing the underlying pattern of human germline mutations: lessons from the factor IX gene , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  W. Linehan,et al.  Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.

[33]  W. Linehan,et al.  Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.

[34]  A. Knudson.  VHL gene mutation and clear-cell renal carcinomas. , 1995, The cancer journal from Scientific American.

[35]  Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. Clinical Research Group for VHL in Japan. , 1995, Human molecular genetics.